SCHEDULE 13G/A: Key Investors Disclose Passive Stake in Dermata Therapeutics

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a passive 0.4% beneficial ownership stake in Dermata Therapeutics, Inc. through an amended Schedule 13G filing.

Summary

• The filing is an Amendment No. 1 to Schedule 13G for Dermata Therapeutics, Inc. common stock.
• The reporting persons are Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.
• As of March 31, 2025, the reporting persons beneficially owned 23,340 shares of Common Stock.
• This beneficial ownership represents approximately 0.4% of the Common Stock outstanding.
• The ownership is based on 5,430,648 shares of Common Stock outstanding as of March 11, 2025, plus the 23,340 shares issuable upon exercise of Intracoastal Warrant 1.
• A second warrant, Intracoastal Warrant 2, for 262,468 shares, is excluded from current beneficial ownership calculations because it is not exercisable until stockholder approval and contains a blocker provision limiting ownership to 4.99%.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a standard regulatory disclosure of a passive, small beneficial ownership stake, which is generally neutral in sentiment. It does not contain performance results or strategic updates.

Positives

• The reporting persons hold warrants, indicating a potential long-term interest in the company's equity.

Negatives

• The disclosed beneficial ownership of 0.4% is a very small, passive stake, indicating limited influence on the company's strategic direction.
• Intracoastal Warrant 2, representing a larger potential stake, is not currently exercisable and is subject to stockholder approval and a 4.99% beneficial ownership blocker provision.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders are informed of the beneficial ownership stake held by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, providing transparency on the company's ownership structure.

Next Steps

• Stockholder approval is required for the exercisability of Intracoastal Warrant 2, which would allow the reporting persons to potentially acquire an additional 262,468 shares.

Key Dates

Keywords

Dermata Therapeutics, SEC filing, Schedule 13G, beneficial ownership, common stock, Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC, warrants